Skip to main content
GALECTIN THERAPEUTICS INC logo

GALECTIN THERAPEUTICS INC — Investor Relations & Filings

Ticker · GALT ISIN · US3632252025 LEI · 5299004HFYSAZM2ALW85 US Manufacturing
Open in API
Filings indexed 1,091 across all filing types
Latest filing 2011-12-20 Regulatory Filings
Country US United States of America
Listing US GALT

About GALECTIN THERAPEUTICS INC

https://galectintherapeutics.com/

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for fibrotic diseases, chronic liver disease, and cancer. The company's therapeutic approach centers on inhibiting the galectin-3 protein, which is implicated in various inflammatory, fibrotic, and malignant conditions. Its lead drug candidate, belapectin (GR-MD-02), is a proprietary carbohydrate-based drug designed to bind to and inhibit galectin-3. The primary development program for belapectin is focused on treating non-alcoholic steatohepatitis (MASH) with cirrhosis, a serious liver disease with no currently approved therapies.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text references a Collaboration, Supply, Marketing and Distribution Agreement as an exhibit, with confidential treatment requested for certain portions. There is no indication of financial statements or quarterly/yearly financial results, nor is this a proxy, earnings release, or management discussion. The document is primarily an announcement of a material event (agreement) and related confidential treatment, typical of an 8-K filing. Given the nature of the content and the form type, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2011-12-20 English
Regulatory Filings 2011
Regulatory Filings
2011-12-20 English
Regulatory Filings 2011
Regulatory Filings Classification · 95% confidence The document is a letter from Galectin Therapeutics Inc. to the SEC Division of Corporation Finance responding to comments on the company's previously filed Form 10-K for the fiscal year ended December 31, 2010. The letter addresses procedural and signature issues related to the 10-K filing rather than containing the 10-K report itself. The document is short (2852 characters) and is a correspondence or regulatory response rather than a full financial report. According to the rules, such correspondence responding to SEC comments on a 10-K is classified as a Regulatory Filing (RNS), not the 10-K itself.
2011-12-19 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate updates. The text includes a press release titled 'Galectin Therapeutics Provides Corporate Update' dated December 19, 2011. The document is short (2654 characters) and primarily serves as an announcement of a corporate update rather than containing detailed financial statements or comprehensive reports. There is no indication of financial results, audit information, or detailed management discussion. The nature of the content fits best with a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into more specific categories like Earnings Release or Annual Report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2011-12-19 English
Regulatory Filings 2011
Regulatory Filings
2011-12-17 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text references a legal dispute resolution and dismissal of lawsuits and arbitration, which is typical content for an 8-K filing. It does not contain financial statements or detailed financial data, nor is it an annual or quarterly report. It is not a proxy, earnings release, or management discussion. The content fits best under Regulatory Filings (RNS) as it is a general regulatory announcement about a legal event and settlement. The document length is short and it is not announcing or attaching a report but reporting an event. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2011-11-22 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.